S
Susumu Kobayashi
Researcher at Beth Israel Deaconess Medical Center
Publications - 648
Citations - 23408
Susumu Kobayashi is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Total synthesis & Epidermal growth factor receptor. The author has an hindex of 62, co-authored 629 publications receiving 21514 citations. Previous affiliations of Susumu Kobayashi include Chiba University & University of Tokyo.
Papers
More filters
Journal Article
Small Symptomatic Pericardial Diverticula Treated by Video-Assisted Thoracic Surgical Resection
TL;DR: It is recommended that a symptomatic anterior mediastinal cyst be completely resected even if it does not appear large enough to compress the neighboring organs.
Journal ArticleDOI
1,3-Rearrangement of ketene-N,O-acetals
TL;DR: In this paper, a chiral quaternary carbon was constructed using a 1,3-rearrangement to obtain a C-alkylated product, which was shown to be opposite to that obtained by an anionic direct dienolate alkylation.
Posted ContentDOI
Long read sequencing reveals a novel class of structural aberrations in cancers: identification and characterization of cancerous local amplifications
Yoshitaka Sakamoto,Liu Xu,Masahide Seki,Toshiyuki T. Yokoyama,Masahiro Kasahara,Yukie Kashima,Akihiro Ohashi,Yoko Shimada,Noriko Motoi,Katsuya Tsuchihara,Susumu Kobayashi,Takashi Kohno,Yuichi Shiraishi,Ayako Suzuki,Yutaka Suzuki +14 more
TL;DR: In this paper, a new class of local structural aberrations in lung cancers was identified, consisting of complex combinations of local duplications, inversions, and micro deletions.
Journal ArticleDOI
Asymmetric total synthesis of 9-methoxystrobilurin K
TL;DR: Asymmetric total synthesis of a potent antifungal and cytostatic 9methoxystrobilurin K was achieved by developing a convergent and versatile synthetic route.
Journal ArticleDOI
Acquired Resistance to the ALK Inhibitor Crizotinib in the Absence of an ALK Mutation
Daniel B. Costa,Susumu Kobayashi +1 more
TL;DR: It is unknown whether emergence of acquired mutations is the main mechanism of resistance to ALK inhibitors in NSCLC, but initial efforts have made to identify mechanisms responsible for acquired resistance to crizotinib and other ALK TKIs.